SAM
VOR icon

Smartleaf Asset Management’s Vor Biopharma VOR Stock Holding History

Smartleaf Asset Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5
Closed -$116 – 2992
2024
Q2 		$116 Buy
+5
New +$162 ﹤0.01% 2716

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Smartleaf Asset Management's VOR Position: Q3 2024 in Review

Smartleaf Asset Management sold out of Vor Biopharma (VOR) in Q3 2024, closing a stake of 5 shares — an estimated $116 sold.

Smartleaf Asset Management first reported a position in VOR in Q2 2024 and held it in 1 quarter. The position peaked at $116 in Q2 2024. 54 funds tracked by Wall St. Rank hold VOR as of Q3 2024.

  • Smartleaf Asset Management reported no remaining Vor Biopharma position as of Q3 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 5 Vor Biopharma shares in Q3 2024, an estimated $116.
  • Smartleaf Asset Management first reported a position in Vor Biopharma in Q2 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Vor Biopharma position peaked at $116 in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2024.

Based on Smartleaf Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.